Scientists have identified a toxic cascade that leads to neuronal degeneration in patients with Parkinson’s disease and figured out how to interrupt it, reports a study. Intervening with an antioxidant early in the disease process may break the degenerative cycle and improve neuron function in Parkinson’s, the study showed. Parkinson’s is second most common neurodegenerative disorder.
A simple scratch-and-sniff test could predict Parkinson’s disease even earlier than previously thought, new research demonstrates. The test could potentially identify certain people who are at an increased risk of developing the disease up to 10 years before they are actually diagnosed.
Researchers asked volunteers to draw a spiral on a sheet of paper. By analyzing how long it took them to draw the spiral and how hard they pressed on the paper with the pen, the team could not only tell which volunteers had Parkinson’s disease, they could also tell how severe it was. Doctors could use the automated system in their surgery to easily diagnose the disease or keep track of the progress of existing patients.
Scientists now have early proof that an antidepressant drug that’s been around for more than 50 years could slow the progression of Parkinson’s.
Using data gathered from 100 million Norwegian prescriptions, researchers have found that asthma medicine can halve a patient’s risk of developing Parkinson´s disease.
Researchers want to prevent alpha-synuclein from accumulating in the brain. To do so, the team searched for drugs that turn down alpha-synuclein production. They then tested the drugs in mice and stem cells and studied in data from the health records of millions of people living in Norway. The results of their efforts, point to a new drug development path for PD.
Japanese neurosurgeons report two new strategies to improve outcomes of iPS cell-based therapies for Parkinson’s disease in monkey brains. The findings are a key step for patient recruitment of the first iPS cell-based therapy to treat neurodegenerative diseases.
By the time Parkinson’s disease manifests as the typical motor dysfunctions, portions of the brain have already been irreversibly destroyed. In search of an early portent of the disease, researchers may now have found one in the gut: they have shown that the bacterial community in the gut of Parkinson’s patients differs from that of healthy people even at a very early stage of the disease.
Researchers have developed a set of tools to observe, monitor and quantify how misfolded proteins associated with Parkinson’s disease enter neurons in laboratory cultures and what happens to them once they’re inside.
A drug commonly used to treat diabetes may have disease-modifying potential to treat Parkinson’s disease, a new study suggests, paving the way for further research to define its efficacy and safety.